A lab in the gray zone<\/h2>\n\n\n\n
Bexorg is based in New Haven, Connecticut, and its technology grew out of Yale-linked research that showed some cellular and metabolic functions could be restored in pig brains hours after death. The company now applies a related approach to postmortem human brains donated specifically for research.<\/p>\n\n\n\n
Also Read: For the first time, a subsea cable will drop to about 13,000 ft. beneath Arctic ice to keep the internet link between Europe and Asia from ever being cut again, and the real driver isn\u2019t engineering, it\u2019s avoiding routes that run through conflict zones\u00a0<\/a><\/h4>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\nThe system, called BrainEx, circulates a custom artificial blood-like solution through the brain\u2019s blood vessels. That fluid supplies oxygen and nutrients, removes waste, and keeps enough cellular activity going for researchers to test drugs and measure biological responses.<\/p>\n\n\n\n
This is not a science-fiction resurrection machine. Bexorg says its research brains have working cells<\/a> but are not connected to a body, nerves, or sense organs, and the company states that perfusion \u201ccan never bring the research brain back to consciousness.\u201d<\/p>\n\n\n\nWhy drug companies care<\/h2>\n\n\n\n
The medical need is enormous. In 2026, an estimated 7.4 million Americans age 65 and older are living with Alzheimer\u2019s<\/a>, while more than 1.1 million people in the U.S. are living with Parkinson\u2019s disease.<\/p>\n\n\n\nFor families, those numbers are not abstract. They are mistaken names at the dinner table, slower steps across the kitchen, and caregivers trying to stretch time a little further.<\/p>\n\n\n\n
Drug developers have struggled because the human brain is hard to model. A therapy may look promising in a mouse or a dish of cells, then fail when tested in people, partly because animal brains cannot fully reflect decades of human aging, medication use, genetics, and environmental exposure.<\/p>\n\n\n\n
The animal-testing question<\/h2>\n\n\n\n
That is where Bexorg\u2019s platform becomes more than a medical story. It also lands in the middle of a wider push to reduce reliance on animal testing in drug development.<\/p>\n\n\n\n
In April 2025, the FDA announced a plan to reduce, refine, or potentially replace some animal testing requirements with human-relevant methods, including AI models, organoids, and lab-based human systems. <\/p>\n\n\n\n
One year later, the agency said more than 90% of drugs that pass animal studies<\/a> still fail to win approval, often because human trials reveal safety or effectiveness problems.<\/p>\n\n\n\nBexorg\u2019s work is not the same as a standard organoid or organ-on-a-chip. It uses whole postmortem brains, which makes the science more realistic in some ways and far more ethically sensitive in others.<\/p>\n\n\n\n
What happens inside BrainEx<\/h2>\n\n\n\n
According to reports based on Science coverage, Bexorg has studied more than 700 human brains using BrainEx. During an experiment, the organ may metabolize a test drug while sensors collect data on cells, proteins, and physiology. After about 24 hours, tissue can be divided into many samples for deeper analysis.<\/p>\n\n\n\n
In practical terms, scientists can now ask questions that are hard to answer in animals. Did the drug reach the right target? How long did it stay active? Did it trigger early signs of side effects?<\/p>\n\n\n\n
\n\n\nAlso Read: Germany is breaking decades of military caution, unlocking multi-billion spending outside its debt limit and accelerating tanks, frigates, and ammunition, as Europe\u2019s biggest economy could start looking like a top-tier warfighting power\u00a0<\/a><\/h4>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\nBexorg says its platform can help researchers understand drug behavior before expensive human trials begin. The company also says the technology allows testing in diseased and non-diseased whole human brains, giving drug developers a closer look at the biology they actually hope to treat.<\/p>\n\n\n\n![\"Laboratory](\"https:\/\/okdiario.com\/techy\/en\/wp-content\/uploads\/2026\/06\/bexorg-brainex-postmortem-brain-drug-testing.jpg\" "\\"\\"")
By maintaining molecular activity in postmortem brains, Bexorg\u2019s BrainEx platform offers a human-centric model for testing neurology drugs.<\/figcaption><\/figure>\n\n\n\nBiohaven enters the picture<\/h2>\n\n\n\n
The business side is already moving. In June 2025, Bexorg announced a multi-program research collaboration with Biohaven to support two preclinical central nervous system drug programs. The goal was to generate data on target engagement, biomarkers, pharmacokinetics, pharmacodynamics, and mechanism of action.<\/p>\n\n\n\n
That is a lot of technical language, but the idea is simple. Before a drug reaches patients, companies want stronger evidence that it goes where it should, acts on the right biology, and does not create obvious warning signs.<\/p>\n\n\n\n
Bexorg later announced that it had raised $42.5 million in total funding to expand its AI and whole-human-brain platform. The company said central nervous system drug development has a clinical trial failure rate above 95%, largely because current models do not capture human biology well enough.<\/p>\n\n\n\n
The consciousness concern<\/h2>\n\n\n\n
Here is the part most people will pause over. If a brain is active enough to respond to drugs, could it ever feel pain, remember, or become aware?<\/p>\n\n\n\n
Bexorg says no. The company states that its research brains do not show the electrical activity needed for thought or physical sensation, and that its perfusion fluid includes anesthesia as an added safeguard.<\/p>\n\n\n\n
Still, bioethicists are watching closely. The ethical issue is not only what the technology does now, but what it might do later if methods improve, experiments last longer, or researchers try to restore more activity.<\/p>\n\n\n\n
A useful model, not a living person<\/h2>\n\n\n\n
There is another limit worth remembering. A postmortem brain on a machine is not the same as a living brain inside a body.<\/p>\n\n\n\n
Blood pressure, immune activity, hormones, sensory input, and a person\u2019s full physiology are missing. Some experts warn that suppressing electrical activity may also affect how the system models real brain function, especially for drugs that influence neural firing<\/a>.<\/p>\n\n\n\n\n\n\nAlso Read: A soil fungus plus broccoli-leaf residue managed to cut a \u201cnearly invisible\u201d nematode that devastates tomato crops by up to 98% in R\u00edo Cuarto, and it didn\u2019t just hit the pest, it also boosted yields by as much as 184%\u00a0<\/a><\/h4>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\nSo, BrainEx is not a perfect window into a living person, but it may be a powerful bridge between animal studies and human trials. That bridge could matter a lot in diseases where failure has become painfully common.<\/p>\n\n\n\n
What comes next<\/h2>\n\n\n\n
At the end of the day, Bexorg\u2019s work forces medicine to sit with two truths at once: the technology could speed up the search for treatments that millions of families desperately need, while it pushes science into a moral gray zone that cannot be handled casually.<\/p>\n\n\n\n
The most responsible path is not panic or hype. It is transparency, strict consent rules, independent bioethics oversight, and clear limits on what researchers are allowed to restore.<\/p>\n\n\n\n
For now, these brains are not awake, but the debate around them certainly is.<\/p>\n\n\n\n
The official statement was published on Bexorg<\/em><\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"A U.S. biotech startup is using donated human brains after death to test experimental drugs for Alzheimer\u2019s, Parkinson\u2019s, and other … <\/p>\n
Why drug companies care<\/h2>\n\n\n\n
The medical need is enormous. In 2026, an estimated 7.4 million Americans age 65 and older are living with Alzheimer\u2019s<\/a>, while more than 1.1 million people in the U.S. are living with Parkinson\u2019s disease.<\/p>\n\n\n\n For families, those numbers are not abstract. They are mistaken names at the dinner table, slower steps across the kitchen, and caregivers trying to stretch time a little further.<\/p>\n\n\n\n Drug developers have struggled because the human brain is hard to model. A therapy may look promising in a mouse or a dish of cells, then fail when tested in people, partly because animal brains cannot fully reflect decades of human aging, medication use, genetics, and environmental exposure.<\/p>\n\n\n\n That is where Bexorg\u2019s platform becomes more than a medical story. It also lands in the middle of a wider push to reduce reliance on animal testing in drug development.<\/p>\n\n\n\n In April 2025, the FDA announced a plan to reduce, refine, or potentially replace some animal testing requirements with human-relevant methods, including AI models, organoids, and lab-based human systems. <\/p>\n\n\n\n One year later, the agency said more than 90% of drugs that pass animal studies<\/a> still fail to win approval, often because human trials reveal safety or effectiveness problems.<\/p>\n\n\n\n Bexorg\u2019s work is not the same as a standard organoid or organ-on-a-chip. It uses whole postmortem brains, which makes the science more realistic in some ways and far more ethically sensitive in others.<\/p>\n\n\n\n According to reports based on Science coverage, Bexorg has studied more than 700 human brains using BrainEx. During an experiment, the organ may metabolize a test drug while sensors collect data on cells, proteins, and physiology. After about 24 hours, tissue can be divided into many samples for deeper analysis.<\/p>\n\n\n\n In practical terms, scientists can now ask questions that are hard to answer in animals. Did the drug reach the right target? How long did it stay active? Did it trigger early signs of side effects?<\/p>\n\n\n\n Bexorg says its platform can help researchers understand drug behavior before expensive human trials begin. The company also says the technology allows testing in diseased and non-diseased whole human brains, giving drug developers a closer look at the biology they actually hope to treat.<\/p>\n\n\n\n The business side is already moving. In June 2025, Bexorg announced a multi-program research collaboration with Biohaven to support two preclinical central nervous system drug programs. The goal was to generate data on target engagement, biomarkers, pharmacokinetics, pharmacodynamics, and mechanism of action.<\/p>\n\n\n\n That is a lot of technical language, but the idea is simple. Before a drug reaches patients, companies want stronger evidence that it goes where it should, acts on the right biology, and does not create obvious warning signs.<\/p>\n\n\n\n Bexorg later announced that it had raised $42.5 million in total funding to expand its AI and whole-human-brain platform. The company said central nervous system drug development has a clinical trial failure rate above 95%, largely because current models do not capture human biology well enough.<\/p>\n\n\n\n Here is the part most people will pause over. If a brain is active enough to respond to drugs, could it ever feel pain, remember, or become aware?<\/p>\n\n\n\n Bexorg says no. The company states that its research brains do not show the electrical activity needed for thought or physical sensation, and that its perfusion fluid includes anesthesia as an added safeguard.<\/p>\n\n\n\n Still, bioethicists are watching closely. The ethical issue is not only what the technology does now, but what it might do later if methods improve, experiments last longer, or researchers try to restore more activity.<\/p>\n\n\n\n There is another limit worth remembering. A postmortem brain on a machine is not the same as a living brain inside a body.<\/p>\n\n\n\n Blood pressure, immune activity, hormones, sensory input, and a person\u2019s full physiology are missing. Some experts warn that suppressing electrical activity may also affect how the system models real brain function, especially for drugs that influence neural firing<\/a>.<\/p>\n\n\n\n So, BrainEx is not a perfect window into a living person, but it may be a powerful bridge between animal studies and human trials. That bridge could matter a lot in diseases where failure has become painfully common.<\/p>\n\n\n\n At the end of the day, Bexorg\u2019s work forces medicine to sit with two truths at once: the technology could speed up the search for treatments that millions of families desperately need, while it pushes science into a moral gray zone that cannot be handled casually.<\/p>\n\n\n\n The most responsible path is not panic or hype. It is transparency, strict consent rules, independent bioethics oversight, and clear limits on what researchers are allowed to restore.<\/p>\n\n\n\n For now, these brains are not awake, but the debate around them certainly is.<\/p>\n\n\n\n The official statement was published on Bexorg<\/em><\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":" A U.S. biotech startup is using donated human brains after death to test experimental drugs for Alzheimer\u2019s, Parkinson\u2019s, and other … <\/p>\nThe animal-testing question<\/h2>\n\n\n\n
What happens inside BrainEx<\/h2>\n\n\n\n
Also Read: Germany is breaking decades of military caution, unlocking multi-billion spending outside its debt limit and accelerating tanks, frigates, and ammunition, as Europe\u2019s biggest economy could start looking like a top-tier warfighting power\u00a0<\/a><\/h4>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
Biohaven enters the picture<\/h2>\n\n\n\n
The consciousness concern<\/h2>\n\n\n\n
A useful model, not a living person<\/h2>\n\n\n\n
Also Read: A soil fungus plus broccoli-leaf residue managed to cut a \u201cnearly invisible\u201d nematode that devastates tomato crops by up to 98% in R\u00edo Cuarto, and it didn\u2019t just hit the pest, it also boosted yields by as much as 184%\u00a0<\/a><\/h4>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
What comes next<\/h2>\n\n\n\n